Christou Niki, Veyrune Léa, Popeskou Sotirios Georgios, Mathonnet Muriel
Digestive Surgery Department, University Hospital of Limoges, 87000 Limoges, France.
Laboratoire EA3842 CAPTuR «Contrôle de l'Activation Cellulaire, Progression Tumorale et Résistances Thérapeutiques», Faculté de Médecine, 2 Rue du Docteur Marcland, 87025 Limoges, France.
J Pers Med. 2021 Jul 1;11(7):630. doi: 10.3390/jpm11070630.
(1) Background: Resistance mechanisms represent a barrier to anti-cancer therapies. Liquid biopsies would allow obtaining additional information in order to develop targeted therapies to thwart the resistance phenomena but also to follow in time real response to treatment and be able to adapt it the most quickly possible way in case of resistance. (2) Methods: herein we summarize the different liquid biopsies which are currently under research; we then review the literature and focalize on one of their potential roles: the theranostic one and especially in the cases of colorectal cancers. (3) Results: few studies targeting liquid biopsy as a potential tool to adapt cancer treatments are present in the literature and encompass few patients. (4) Conclusions: further research is needed to prove the efficiency of LB. Indeed, it seems a promising tool to guide treatment by targeting actionable mutations with detection of resistant mutations.
(1) 背景：耐药机制是抗癌治疗的障碍。液体活检有助于获取更多信息，以开发靶向治疗方法来对抗耐药现象，还能及时跟踪治疗的实际反应，并在出现耐药时尽快调整治疗方案。(2) 方法：在此，我们总结了目前正在研究的不同液体活检方法；然后回顾文献并聚焦于其潜在作用之一：治疗诊断作用，尤其是在结直肠癌病例中。(3) 结果：文献中针对液体活检作为调整癌症治疗潜在工具的研究较少，且涉及的患者数量不多。(4) 结论：需要进一步研究来证明液体活检的有效性。实际上，通过检测耐药突变来靶向可操作突变以指导治疗，它似乎是一种很有前景的工具。
